Therefore, despite lack of AT1 receptor blockade with an ARB, AT2 receptor activation in the cerebrovasculature might be beneficial for the prevention and treatment of cognitive decline caused by transient cerebral ischemia with Aβ infusion, besides of its classical vascular protection. This evidence concerns the gene AGTR1 and transient ischemic attack.